Capital World Investors Has $97.90 Million Stake in First Advantage Co. (NYSE:FA)

Capital World Investors lifted its holdings in First Advantage Co. (NYSE:FA - Free Report) by 246.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,227,076 shares of the company's stock after acquiring an additional 3,718,096 shares during the period. Capital World Investors owned approximately 3.03% of First Advantage worth $97,903,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of FA. Summit Investment Advisors Inc. grew its stake in First Advantage by 15.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,267 shares of the company's stock worth $117,000 after buying an additional 832 shares in the last quarter. Advisory Research Inc. lifted its holdings in shares of First Advantage by 0.6% in the fourth quarter. Advisory Research Inc. now owns 212,446 shares of the company's stock worth $3,979,000 after acquiring an additional 1,216 shares during the last quarter. Corebridge Financial Inc. lifted its holdings in shares of First Advantage by 9.6% in the fourth quarter. Corebridge Financial Inc. now owns 29,784 shares of the company's stock worth $558,000 after acquiring an additional 2,607 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in shares of First Advantage by 17.6% in the fourth quarter. Oppenheimer Asset Management Inc. now owns 19,626 shares of the company's stock worth $368,000 after acquiring an additional 2,938 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in shares of First Advantage by 7.2% in the fourth quarter. Alliancebernstein L.P. now owns 59,600 shares of the company's stock worth $1,116,000 after acquiring an additional 4,000 shares during the last quarter. 94.91% of the stock is currently owned by institutional investors and hedge funds.

First Advantage Trading Down 1.6 %

First Advantage stock traded down $0.23 during mid-day trading on Friday, hitting $14.05. 1,307,715 shares of the stock were exchanged, compared to its average volume of 761,814. The company has a quick ratio of 3.85, a current ratio of 3.85 and a debt-to-equity ratio of 0.61. First Advantage Co. has a 12 month low of $12.32 and a 12 month high of $20.79. The firm's fifty day simple moving average is $14.43 and its two-hundred day simple moving average is $17.27. The stock has a market capitalization of $2.44 billion, a price-to-earnings ratio of 468.33 and a beta of 1.20.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. BMO Capital Markets dropped their target price on shares of First Advantage from $24.00 to $22.00 and set an "outperform" rating for the company in a report on Monday, March 3rd. William Blair reiterated an "outperform" rating on shares of First Advantage in a report on Friday, February 28th. Royal Bank of Canada reiterated an "outperform" rating and issued a $22.00 price objective on shares of First Advantage in a report on Thursday, January 23rd. Finally, Barclays reiterated an "equal weight" rating and issued a $15.00 price objective (down previously from $20.00) on shares of First Advantage in a report on Thursday, April 10th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, First Advantage currently has an average rating of "Moderate Buy" and a consensus price target of $65.80.

About First Advantage

First Advantage Corporation provides employment background screening, identity, and verification solutions worldwide. It offers pre-onboarding products and solutions, such as criminal background checks, drug/health screening, extended workforce screening, FBI channeling, identity checks and biometric fraud mitigation tools, education/work history verification, driver records and compliance, healthcare credentials, executive screening, and other screening products.